FINWIRES · TerminalLIVE
FINWIRES

Nippon Concrete Industries to Absorb Wholly-Owned Subsidiary, Eyes Extraordinary Loss

By

Nippon Concrete Industries (TYO:5269) has approved an absorption-type merger of its wholly-owned subsidiary, NC Management Service (NCMS), effective Oct. 1, according to a Tokyo bourse filing on Friday.

The merger aims to improve group management efficiency and consolidate operations, as NCMS manages land and buildings used by manufacturing subsidiaries within the group.

Since NCMS is a wholly-owned subsidiary, the merger will be carried out under simplified procedures without requiring a shareholder vote at the subsidiary level.

The company expects to record a loss on extinguishment of tie-in shares as an extraordinary loss in its non-consolidated financial results, though the exact amount has not yet been determined.

Related Articles

Asia

CSPC Innovation Pharma Gets China Nod for Psoriasis Drug

CSPC Innovation Pharmaceutical (SHE:300765, HKG:1093) received drug registration from China's medical products administrator for ustekinumab injection.The drug, branded as Enyike, is used to treat moderate to severe plaque psoriasis, according to Friday filings with the Shenzhen and Hong Kong bourses.

$HKG:1093$SHE:300765
Asia

Minda's Consolidated Profit More Than Doubles in Fiscal Q4

Minda (NSE:MINDACORP, BOM:538962) posted a sharp increase in its attributable consolidated profit after tax to 1.25 million Indian rupees in the fiscal fourth quarter ended March 31 from 520.3 million rupees a year ago.Earnings per share climbed to 5.21 rupees from the year-ago figure of 2.18 rupees, according to a Friday filing to the Indian stock exchanges by the auto components manufacturer.Revenue from operations in fiscal Q4 also increased to 17.0 billion rupees from 13.2 billion rupees a year earlier.The board recommended a final dividend of 0.80 rupees per share for the fiscal year ended March 31.Shares of the company jumped nearly 8% in after-market hours.

$BOM:538962$NSE:MINDACORP
Asia

Apeloa Pharmaceutical Gets US FDA Nod for Hypertension, Angina Treatment

The U.S. Food and Drug Administration approved Apeloa Pharmaceutical's (SHE:000739) metoprolol succinate extended-release tablets, according to a Friday disclosure to the Shenzhen bourse.The drug is indicated for hypertension and angina pectoris or chest pain, as well as symptomatic stable chronic heart failure with dysfunction in the left ventricle, among others.

$SHE:000739